PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Pyrolysis”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 793 records · Page 44Linked to original sources
PubMed1989

[Occupational toxicology and safety technology risk assessment in pyrolysis gases of plastics].

The evaluation of occupational and safety risk by thermal decomposition products of plastics can be obtained not theoretically, but principally only by practice-related experiments due to influence of a lot of external conditions. We present a 200 l-experimental chamber, in which we can expose original samples up to 8 X 8 cm at temperatures up to 1000 degrees C. It is possible to evaluate the risk by extrapolation of values from the experiments, obtained by discontinuous or automatic chemical analyses, to the plants data and comparison with MAC's and other safety values. The kind of appreciation is illustrated by an example, the thermal processing of 80 kg polyethylene in a industrial hall of 11500 m3.

Air Pollutants, Occupational↗
PubMed1987

[Th role of human intestinal flora on the metabolic activation of pyrolysis products].

The role of the intestinal flora on the metabolic activation of dipyrido 1,2-a:3',2'-d imidazole compounds was investigated with the Salmonella typhimurium test system, using strain TA98. The metabolic activation mixture was obtained from cell-free extracts from E. coli, B. fragilis and Cl. perfringens. Whereas these extracts were able to activate 2-AA (used as control), the 2 and 3 amino derivatives of dipyrido [1,2-a:3',2'-d] imidazole were not revealed as mutagenic.

Amines↗
PubMed1988

Carcinogenic glutamic acid pyrolysis product in the dialysate of uremic patients treated by continuous ambulatory peritoneal dialysis.

By using a high-performance liquid chromatography (HPLC) method, we determined the contents of 2-amino-6-methyldipyrido[1,2-a:3', 2'-d] imidazole (Glu-P-1) and 2-aminodipyrido[1,2-a:3', 2'-d]imidazole (Glu-P-2) in the dialysate of patients with uremia. The total dialysate (approximately 6 liters) per day of the patients who had received continuous ambulatory peritoneal dialysis (CAPD) was examined. The amounts of Glu-P-1 and Glu-P-2 in the total dialysate per day were 552.2 +/- 266.9 pmole and 386.3 +/- 146.0 pmole (mean +/- SD, n = 10), respectively. The recoveries of Glu-P-1 and Glu-P-2 in the dialysate on our assay method were 68.2% and 54.3%, respectively. Based on the recoveries, the average amounts of Glu-P-1 and Glu-P-2 in the dialysate of uremic patients were assumed to be 809.7 pmole and 711.4 pmole, respectively.

Adult↗
PubMed1987

Accumulation of 2-amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole and 2-aminodipyrido[1,2-a:3',2'-d]imidazole, carcinogenic glutamic acid pyrolysis products, in plasma of patients with uremia.

In order to investigate the exposure of humans to 2-amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole [(Glu-P-1) Chemical Abstracts Service:67730-11-4] and 2-aminodipyrido[1,2-a:3',2'-d]imidazole [(Glu-P-2) Chemical Abstracts Service:67730-10-3], carcinogenic heterocyclic amines, we developed a high-performance liquid chromatography method to detect Glu-P-1 and Glu-P-2 in biological samples, and compared the plasma levels of the carcinogens in normal subjects with those in uremic patients in which higher incidence of malignancy has been reported. Glu-P-1 and Glu-P-2 levels in plasma of uremic patients before induction of hemodialysis treatment were 12.62 +/- 3.65 (SD) pmol/ml (n = 5) and 14.81 +/- 5.17 pmol/ml (n = 5), respectively, whereas Glu-P-1 and/or Glu-P-2 could be detected in only two of seven normal subjects and the levels were lower than 3.1 pmol/ml. Approximately 10% of these carcinogens in plasma of uremic patients could be removed by the first hemodialysis treatment, and reasonable amounts of these carcinogens could be detected in the dialysate of uremic patients. However, significant amounts of Glu-P-1 and Glu-P-2 were still detected in plasma of all uremic patients even after 1 month-hemodialysis treatments. These results suggest that one of the excretory pathways of these carcinogens is via kidney.

Adult↗